TY - JOUR
T1 - Biomarkers of Alzheimer's disease and mild cognitive impairment
T2 - A current perspective
AU - Lewczuk, Piotr
AU - Mroczko, Barbara
AU - Fagan, Anne
AU - Kornhuber, Johannes
N1 - Funding Information:
PL is supported by a grant from the German Bundesministerium für Bildung und Forschung (grant 01ED1203D ) within the BiomarkAPD Project of the JPND, and holds the position of visiting professor at the Medical University of Bialystok (Poland). BM is supported by the Leading National Research Centre in Białystok (KNOW) (grants for neurodegenerative diseases, Medical University of Bialystok, Poland). AF is supported by grants from the National Institute on Aging of the National Institutes of Health (USA) , the DIAN Pharma Consortium and the Alzheimer's Association .
Publisher Copyright:
© 2014 Medical University of Bialystok. Published by Elsevier Urban &Partner Sp. z o.o. All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - A growing body of evidence supports the application of the neurochemical dementia diagnostics (NDD) biomarkers for the diagnosis of dementing conditions. Biomarkers of Alzheimer's disease (AD) were recently classified as these reflecting amyloid β pathology (decreased CSF concentrations of Aβ42 and/or positive Aβ PET scan) and these reflecting neurodegeneration (increased CSF Tau concentrations, decreased uptake of FDG on FDG-PET, and cerebral atrophy on structural MRI). Particularly important seems the role of the biomarkers in the early diagnosis of AD, as the first pathophysiologic events observable in the CSF and amyloid β-PET occur years and perhaps decades before the onset of the earliest clinical symptoms. Therefore, the NDD tools enable the diagnosis of AD already in the early preclinical stage. This review summarizes pathophysiology underlying the CSF biomarkers, following a discussion of their role in the current guidelines for the diagnostic procedures.
AB - A growing body of evidence supports the application of the neurochemical dementia diagnostics (NDD) biomarkers for the diagnosis of dementing conditions. Biomarkers of Alzheimer's disease (AD) were recently classified as these reflecting amyloid β pathology (decreased CSF concentrations of Aβ42 and/or positive Aβ PET scan) and these reflecting neurodegeneration (increased CSF Tau concentrations, decreased uptake of FDG on FDG-PET, and cerebral atrophy on structural MRI). Particularly important seems the role of the biomarkers in the early diagnosis of AD, as the first pathophysiologic events observable in the CSF and amyloid β-PET occur years and perhaps decades before the onset of the earliest clinical symptoms. Therefore, the NDD tools enable the diagnosis of AD already in the early preclinical stage. This review summarizes pathophysiology underlying the CSF biomarkers, following a discussion of their role in the current guidelines for the diagnostic procedures.
KW - Alzheimer's disease
KW - Amyloid β Tau
KW - Cerebrospinal fluid
KW - Clinical neurochemistry
UR - http://www.scopus.com/inward/record.url?scp=84927605569&partnerID=8YFLogxK
U2 - 10.1016/j.advms.2014.11.002
DO - 10.1016/j.advms.2014.11.002
M3 - Review article
C2 - 25579841
AN - SCOPUS:84927605569
SN - 1896-1126
VL - 60
SP - 76
EP - 82
JO - Advances in Medical Sciences
JF - Advances in Medical Sciences
IS - 1
ER -